CoChat

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

Open access
Mathieu, Chantal, Hollander, Priscilla, Miranda-Palma, Bresta, Cooper, John, Franek, Edward, Russell-Jones, David, Larsen, Jens, Tamer, Søren Can, Bain, Stephen C., on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators · 2013 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This study investigated the efficacy and safety of insulin degludec (IDeg) once daily (OD), varying injection timing day to day in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, open-label, treat-to-target, noninferiority trial compared IDeg forced flexible (Forced-Flex) OD (given in a fixed schedule with a minimum 8 and maximum 40 hours between doses) with IDeg or insulin glargine (IGlar) given at the same time daily OD. In the 26-week extension, all IDeg subjects were transferred to a free-flexible (Free-Flex) regimen, which allowed any-time-of-day dosing, and compared with subjects continued on IGlar. RESULTS: After 26 treatment weeks, mean glycosylated hemoglobin was reduced with IDeg Forced- Flex (-0.40%), IDeg (-0.41%), and IGlar (-0.58%). IDeg Forced-Flex noninferiority was achieved. Fasting plasma glucose reductions were similar with IDeg Forced-Flex and IGlar but greater with IDeg (-2.54 mmol/L) than IDeg Forced-Flex (-1.28 mmol/L) (P = .021). At week 52, IDeg Free-Flex subjects had similar glycosylated hemoglobin but greater fasting plasma glucose reductions than IGlar subjects (-1.07 mmol/L) (P = .005). Confirmed hypoglycemia rates (plasma glucose <3.1 mmol/L or severe hypoglycemia) were similar at weeks 26 and 52. Nocturnal confirmed hypoglycemia was lower with IDeg Forced-Flex vs IDeg (37%; P = .003) and IGlar (40%; P = .001) at week 26 and 25% lower with IDeg Free-Flex vs IGlar (P = .026) at week 52. CONCLUSIONS: IDeg can be administered OD at any time of day, with injection timing varied without compromising glycemic control or safety vs same-time-daily IDeg or IGlar. This may improve basal insulin adherence by allowing injection-time adjustment according to individual needs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-3249

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Glycemic efficacy: mean HbA1c ± SEM over time (A) and mean FPG ± SEM over time (B). Plotted data are reported mean values for all randomized participants (FAS). Estimated treatment differences are based on FAS. Last observation carried forward is used for each postbaseline time point in A and B. Subjects randomized to the IDeg Forced-Flex and IDeg treatment arms during the main trial period had the opportunity to continue in the IDeg Free-Flex arm after 26 weeks of treatment.
Figure 1. Glycemic efficacy: mean HbA1c ± SEM over time (A) and mean FPG ± SEM over time (B). Plotted data are reported mean values for all randomized participants (FAS). Estimated treatment differences are based on FAS. Last observation carried forward is used for each postbaseline time point in A and B. Subjects randomized to the IDeg Forced-Flex and IDeg treatment arms during the main trial period had the opportunity to continue in the IDeg Free-Flex arm after 26 weeks of treatment.CC BY-NC · PubMed Central
Figure 2. Hypoglycemia over time, weeks 0–52: severe hypoglycemia (A); overall confirmed hypoglycemia (B); and nocturnal confirmed hypoglycemia (C). Cumulative event rates are based on safety analysis set. Percentage risk reductions refer to delta risks based on estimated rate ratios (FAS). Subjects randomized to the IDeg Forced-Flex and IDeg treatment arms during the main trial period had the opportunity to continue in the IDeg Free-Flex arm after 26 weeks of treatment.
Figure 2. Hypoglycemia over time, weeks 0–52: severe hypoglycemia (A); overall confirmed hypoglycemia (B); and nocturnal confirmed hypoglycemia (C). Cumulative event rates are based on safety analysis set. Percentage risk reductions refer to delta risks based on estimated rate ratios (FAS). Subjects randomized to the IDeg Forced-Flex and IDeg treatment arms during the main trial period had the opportunity to continue in the IDeg Free-Flex arm after 26 weeks of treatment.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 5

  1. Anderson, 2003, Self-reported compliance with insulin injection therapy in subjects with type 1 and type 2 diabetes, Diabetes Metab, 29, A275
  2. Jonassen, 2010, Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation, Diabetes, 59, A11
  3. Heise, 2011, Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine, Diabetes, 60, LB11
  4. Lantus, 2007, Lantus package insert
  5. Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state, Diabetes, 60, A263

Cited by

Items 101–200 of 218

Metadata

Authors
Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • Baylor University Medical Center (US)
  • University of Miami (US)
  • Stavanger University Hospital (NO)
  • Central Clinical Hospital (PL)
  • Royal Surrey County Hospital (GB)
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk A/S (J.L., S.C.T.), DK-2860 Søborg, Denmark
  • Swansea University (GB)
Corresponding author
Mathieu, Chantal
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2013-03-01
Volume
98
Issue
3
Pages
1154-1162
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2044617125
Cited by
219
References
25
Citations by year
2026: 1 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 11 · 2021: 12 · 2020: 10 · 2019: 11 · 2018: 19 · 2017: 27 · 2016: 24 · 2015: 27 · 2014: 29 · 2013: 24
FWCI
27.32
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Cardiff University
  • European Foundation for the Study of Diabetes
  • Novo Nordisk
  • Servier
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
insulin degludec, insulin glargine, type 1 diabetes, basal insulin, flexible dosing, injection timing, HbA1c, fasting blood glucose, hypoglycemia, nocturnal hypoglycemia, insulin adherence, basal insulin therapy, non-inferiority, glycemic control, long-acting insulin analogues
MeSH terms
Insulin Glargine, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Self Administration, Treatment Outcome, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.